Schiff Hardin is pleased to announce that three Intellectual Property Practice Group attorneys have been recognized as IP Stars in Illinois for 2020 by Managing Intellectual Property.
Schiff Hardin is pleased to announce that five practice areas have been ranked in Chambers USA 2020 guide, up one from 2019 with a first-time ranking for Energy & Natural Resources.
Although it is generally accepted that tattoos are copyrightable, one of the only definitive judicial statements on the issue came by way of a preliminary injunction hearing in 2011 involving Mike Tyson’s famous tribal face tattoo, wherein Judge Perry of the Eastern District of Missouri stated, “
The US Court of Appeals for the Federal Circuit recently ruled that color marks can be inherently distinctive when applied to product packaging trade dress. The CAFC upends a long-held understanding that color marks can never be inherently distinctive. Although such marks are considered inherently d
A recently-proposed bipartisan federal bill (SHOPSAFE Act of 2020) would create contributory liability for e-commerce platforms that fail to take steps to limit third-party sales of dangerous counterfeit products.
As local and national governments take measures to combat the spread of COVID-19, patent, trademark and copyright owners are facing potential difficulties with meeting prosecution and dispute deadlines.
The United States Patent and Trademark Office recently announced that it will provide a 30-day extension for many patent and trademark filing and fee deadlines to those personally affected by COVID-19.
LOSANGELES — Craig Gelfound, head of Arent Fox LLP’s Intellectual Property practice in Los Angeles, has once again been honored by the Daily Journal as one of the Top Intellectual Property Lawyers in California, marking his tenth consecutive year of this recognition.
On March 30, 2020, the US District Court for the District of New Jersey affirmed an award of spoliation sanctions, forensic audit, and attorney’s fees in favor of Arent Fox client Sabinsa Corporation.
Teva Pharmaceuticals filed suit against the United States Food and Drug Administration (FDA) alleging that its glatiramer (Copaxone) falls under the revised definition of a “biological product” and should be transitioned to the system established by the Biologics Price Competition and Innovation Act of 2009 (BPCIA).
Partner Joel Wallace shared his insight on the updated guidelines from the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) on running clinical trials and the potential effects of the COVID-19 pandemic on those trials.
The U.S. Food and Drug Administration (FDA) issued a guidance document today outlining its procedures for conducting clinical trials of investigational products in view of the worldwide COVID-19 outbreak.
On April 2, join USPTO officials and Arent Fox Partner Marylee Jenkins, Former Chair of the ABA-IPL Section and USPTO’s Patent Public Advisory Committee (PPAC), for the “Ask the USPTO: The Future of Artificial Intelligence” panel.
Arent Fox LLP is pleased to announce the expansion of its Patent practice and Life Sciences group with the addition of Counsels Daniel C. Stelter and Laurence H. Posorske, Ph.D. Mr. Stelter joins the firm’s San Francisco office, while Mr. Posorske joins Arent Fox in Washington, DC.
The U.S. Food and Drug Administration (FDA) issued a final rule last week that broadened the scope of the Biologics Price Competition and Innovation Act (BPCIA) to include large proteins, even those that could have been previously governed by the Hatch-Waxman Act.